Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Platinum-Resistant Ovarian Carcinoma: early-phase trial registry
5 of 6 indexed Recurrent Platinum-Resistant Ovarian Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Platinum-Resistant Ovarian Carcinoma: 6 US clinical trials tracked, 5 recruiting.
Recurrent Platinum-Resistant Ovarian Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition recurrent-platinum-resistant-ovarian-carcinoma
OPEN 5 | RECR 83% | LATE 0 | EARLY 6 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)
Recurrent Platinum-Resistant Ovarian Carcinoma lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Platinum-Resistant Ovarian Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Platinum-Resistant Ovarian Carcinoma is recruiting above its size-band peers.
5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Platinum-Resistant Ovarian Carcinoma research.
National Cancer Institute (NCI) accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Platinum-Resistant Ovarian Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Recurrent Platinum-Resistant Ovarian Carcinoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
National Cancer Institute (NCI)
NCT05950464
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT04633239
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
NCT05691504
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
NCT06964009
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
NCT06483048
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
City of Hope Medical Center
NCT03113487
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Platinum-Resistant Ovarian Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Platinum-Resistant Ovarian Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Platinum-Resistant Ovarian Carcinoma page
6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Recurrent Platinum-Resistant Ovarian Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Platinum-Resistant Ovarian Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Platinum-Resistant Ovarian Carcinoma condition card totals 6 registered trials; most-linked intervention Biospecimen Collection; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.